Endocrinology Research Analysis
Q2 2025 endocrinology coalesced around mechanistic and translational advances in metabolic liver disease, adipose biology, and neuroendocrine circuits, alongside implementation-grade diagnostics and foundational pharmacology. Multiple complementary liver studies reframed MASH pathogenesis and treatment—from ketogenesis as a hepatoprotective axis and a splicing–IDH1–ammonia checkpoint to a mycobiome-driven CerS6–ceramide pathway—while a phase 3 trial of semaglutide delivered histologic benefit in
Summary
Q2 2025 endocrinology coalesced around mechanistic and translational advances in metabolic liver disease, adipose biology, and neuroendocrine circuits, alongside implementation-grade diagnostics and foundational pharmacology. Multiple complementary liver studies reframed MASH pathogenesis and treatment—from ketogenesis as a hepatoprotective axis and a splicing–IDH1–ammonia checkpoint to a mycobiome-driven CerS6–ceramide pathway—while a phase 3 trial of semaglutide delivered histologic benefit in F2–F3 MASH. Spatial single-cell and zonal genetics redefined hepatic glucose and lipid control, enabling conceptual decoupling of steatosis from glycemia. An adipose progenitor (CP‑A) pool explained age-related visceral adiposity, and an adipose-to-brain GDF15→GFRAL circuit causally linked lipolysis to anxiety-like behavior. Methodologically, a first-in-class BMAL1 modulator opened practical circadian pharmacology, and a retinal image deep-learning system for DKD showcased scalable, multi-ethnic, prospective validation.
Selected Articles
1. Pharmacological targeting of BMAL1 modulates circadian and immune pathways.
A selective small molecule binding BMAL1's PASB domain remodels clock protein conformation, shifts cellular circadian oscillations, and dampens macrophage inflammatory programs, providing a validated chemical probe for clock-directed therapeutics.
Impact: Opens tractable circadian pharmacology with direct functional consequences across immunometabolism, catalyzing a new therapeutic class.
Clinical Implications: Clock-directed modulators could treat circadian-linked inflammatory and metabolic diseases and enable phenotype-based patient stratification, pending in vivo PK/PD and safety.
Key Findings
- Discovery of a BMAL1 PASB-binding small molecule that remodels BMAL1 conformation.
- Dose-dependent phase shifts in cellular circadian oscillations and suppression of inflammatory/phagocytic programs.
- Biochemical, structural, and cellular validation of target engagement.
2. GDF15 links adipose tissue lipolysis with anxiety.
β-adrenergic lipolysis induces adipose GDF15 via M2-like macrophages, and GFRAL signaling is required for stress-induced anxiety-like behavior, defining an adipose-to-brain endocrine circuit.
Impact: Establishes a causal neuroendocrine axis connecting peripheral metabolic mobilization to behavior, with implications across metabolic and psychiatric medicine.
Clinical Implications: Supports monitoring for neuropsychiatric effects when therapeutically elevating GDF15 and motivates exploration of GDF15–GFRAL antagonism to mitigate stress-related anxiety.
Key Findings
- Stress and β3-agonism induce GDF15 secretion from adipose tissue.
- GDF15 induction depends on lipolysis via M2-like macrophage activation.
- GFRAL is necessary for anxiety-like behavior in mice.
3. Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction-associated steatotic liver disease progression.
Minor intron splicing defects in MASH trigger Insig1/2 intron retention, SREBP1c activation, and IDH1-dependent reductive carboxylation, fueling lipogenesis and ammonia accumulation to initiate fibrosis; targeting IDH1, clearing ammonia, or restoring splicing mitigated fibrosis in models.
Impact: Defines a splicing–metabolism checkpoint with multiple action points (IDH1, ammonia handling, splicing restoration) for antifibrotic strategies.
Clinical Implications: Prioritizes development of IDH1 inhibitors and ammonia-lowering approaches and motivates biomarker programs based on minor intron retention for patient stratification.
Key Findings
- Minor intron splicing is disrupted in MASH, promoting Insig1/2 intron retention and SREBP1c activation.
- IDH1-driven reductive carboxylation fuels lipogenesis and ammonia accumulation, initiating fibrosis.
- Blocking IDH1, clearing ammonia, or restoring splicing attenuates fibrosis in models.
4. Distinct adipose progenitor cells emerging with age drive active adipogenesis.
Lineage tracing, transplantation, and single-cell profiling identify an age-enriched committed preadipocyte population (CP‑A) that expands in mid-life and drives visceral adipogenesis dependent on LIFR signaling.
Impact: Mechanistically explains age-related visceral adiposity via a targetable progenitor pool and signaling dependency.
Clinical Implications: Enables development of LIFR-pathway inhibitors or progenitor-directed strategies to prevent or reverse visceral adiposity; biomarkers of CP‑A activity could guide selection.
Key Findings
- Mid-life visceral adipogenesis is extensive despite low turnover in youth.
- CP‑A progenitors expand with age and show high adipogenic capacity.
- LIFR signaling is required for CP‑A–driven adipogenesis.
5. Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling.
Zonally targeted disruption shows periportal versus pericentral hepatic insulin resistance produce divergent phenotypes, nominating strategies to reduce steatosis without worsening glycemia.
Impact: Recasts hepatic insulin resistance as spatially heterogeneous with actionable zonal targets, enabling decoupling of steatosis from systemic glycemia.
Clinical Implications: Supports development of pericentral-selective signaling modulators or downstream adaptations to treat fatty liver while preserving glucose control.
Key Findings
- Periportal insulin resistance increases gluconeogenesis but reduces lipogenesis/steatosis.
- Pericentral insulin resistance lowers pericentral steatosis while preserving systemic glucose control.
- Metabolic flux reallocation contributes to preserved glycemia.
6. Ketogenesis mitigates metabolic dysfunction-associated steatotic liver disease through mechanisms that extend beyond fat oxidation.
Human isotope fluxomics integrated with genetic mouse models show that maintaining hepatic ketogenesis protects against MASLD/MASH via mechanisms beyond total fat oxidation; disrupting BDH1 lowers oxidation without worsening injury.
Impact: Elevates ketogenesis from a byproduct to a hepatoprotective signaling axis and therapeutic/biomarker candidate.
Clinical Implications: Motivates trials of pharmacologic or nutritional strategies to enhance hepatic ketogenesis and development of ketone flux biomarkers for stratification.
Key Findings
- Liver injury correlates with ketogenesis and total fat oxidation but not TCA turnover.
- Hepatic HMGCS2 loss induces MASLD/MASH-like injury.
- BDH1 disruption lowers oxidation without exacerbating injury, implying protective ketone signaling.
7. Spatial hepatocyte plasticity of gluconeogenesis during the metabolic transitions between fed, fasted and starvation states.
Single-cell and spatial analyses reveal that gluconeogenesis shifts from periportal dominance to include robust pericentral activity during prolonged fasting/starvation, with suppression of β-catenin signaling and glutamine flux reprogramming.
Impact: Challenges static zonation and ties signaling/substrate flux to state-dependent hepatic glucose output, reshaping therapeutic strategies and tracer interpretations.
Clinical Implications: Supports interventions modulating β-catenin and glutamine flux to lower hepatic glucose output without worsened metabolic endpoints.
Key Findings
- Gluconeogenic programs are spatially and temporally plastic across the lobule.
- Starvation suppresses canonical β-catenin signaling throughout the lobule.
- Glutamine reprogramming enhances incorporation into glucose under starvation.
8. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis.
Preclinical studies identify a symbiotic gut filamentous fungus whose metabolite modulates host CerS6–ceramide signaling to ameliorate MASH, establishing a causal mycobiome–sphingolipid axis.
Impact: Expands therapeutic concepts beyond bacteriome to a defined mycobiome–lipid pathway with translational potential.
Clinical Implications: Motivates mycobiome/metabolite diagnostics and CerS6-modulating therapeutics; requires human validation and biomarker development.
Key Findings
- Isolation of a gut filamentous fungus linked to improved MASH phenotypes.
- A fungal secondary metabolite attenuates steatohepatitis via CerS6–ceramide signaling.
- Causal link between a mycobiome member and host sphingolipid metabolism.
9. Non-invasive biopsy diagnosis of diabetic kidney disease via deep learning applied to retinal images: a population-based study.
A retinal image–based deep learning system (pretrained on >700,000 images) detected DKD and differentiated diabetic from non-diabetic nephropathy across multi-ethnic cohorts with prospective and longitudinal validation.
Impact: Demonstrates a scalable, externally validated AI pathway for noninvasive DKD screening and biopsy decision support.
Clinical Implications: Integrate retinal AI with albuminuria/eGFR to prioritize referrals, intensify renoprotective therapy, and flag suspected non-diabetic pathology; implementation trials should assess outcomes and fairness.
Key Findings
- Internal DKD AUC ~0.84; external AUCs ~0.79–0.83 across multi-ethnic datasets.
- Differentiation of diabetic nephropathy vs NDKD with high AUC across datasets.
- Prospective sensitivity gains and 4.6-year divergent eGFR decline by AI-defined groups.
10. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
A 72-week interim analysis of a double-blind phase 3 RCT in biopsy-proven MASH (F2–F3) showed weekly semaglutide 2.4 mg significantly increased NASH resolution and fibrosis improvement versus placebo, with greater weight loss.
Impact: First large phase 3 RCT to demonstrate histologic benefit of a GLP-1RA in MASH, addressing a major unmet need.
Clinical Implications: Semaglutide 2.4 mg weekly may be considered for F2–F3 MASH pending full outcome data; monitor GI tolerability.
Key Findings
- NASH resolution without fibrosis worsening: 62.9% vs 34.3%.
- Fibrosis improvement without NASH worsening: 36.8% vs 22.4%.
- Mean body weight change −10.5% vs −2.0%; GI AEs more frequent with semaglutide.